NCoR is a corepressor of several transcription factors, including the PPAR family of nuclear receptors in fat and muscle. By specifically deleting NCoR in these tissues, Li et al. and Yamamoto et al. now uncover an important role for NCoR in regulating lipid homeostasis through the coordinated control of different nuclear receptors.
Nuclear receptors are a family of transcription factors that play a key role in receiving signals and modulating responses that drive lipid and carbohydrate metabolism (Rosen and Spiegelman, 2006) . Nuclear receptors also control the development of specific types of fat and muscle cells, which are crucial for maintaining metabolic balance (Spiegelman and Heinrich, 2004) . These diverse functions of nuclear receptors are regulated by the properties of the complexes they form in response to ligand binding (Perissi et al., 2010) . When nuclear receptors are not bound to ligand, they interact with corepressor proteins that maintain them in the inactive state. Upon ligand binding, nuclear receptors dissociate from these silencing factors and assemble with coactivators, which then modulate histone acetylation or chromatin remodeling.
Many nuclear receptors are regulated in this fashion, but perhaps the best-studied group is the PPAR family. These proteins form complexes with coactivators, such as CBP, PGC-1, and CRTC2, and with the corepressors NCoR and SMRT (Chen and Evans, 1995) . Although the coactivators have received great attention, it is not well understood how the corepressors modulate energy metabolism. In this issue of Cell, two studies (Li et al., 2011; Yamamoto et al., 2011) shed important light on the physiological role of the corepressor NCoR, including how it regulates the transcriptional activity of PPARg and how nutritional status might coordinate responses to caloric excess by controlling its expression.
Constitutive deletion of NCoR is embryonically lethal in mice and causes defects in multiple organs. Olefsky and coworkers (Li et al., 2011) generate mice with the NCoR gene specifically deleted in adipose tissue. When fed normal chow, these mice display few changes compared to wild-type animals, but they gain excessive weight when placed on a high-fat diet. Interestingly, this adiposespecific deletion of NCoR induces similar phenotypes in the diet-induced obese mice as those observed when PPARg is activated by thiazolidinedione (TZD) ligands, including improved insulin sensitivity in fat, liver, and muscle and decreased hepatic steatosis (i.e., fatty liver). The targeted deletion of NCoR also produces a gene expression profile similar to that seen with TZDs. However, these mutant mice did not undergo hemodilution (i.e., increased fluid in the plasma) or cardiomegaly (i.e., an enlarged heart), two well-established side effects of TZDs. These results indicate that activation of PPARg specifically in adipose tissue can account for the beneficial insulin-sensitizing effects of TZDs, whereas activation in other tissue, perhaps the kidneys, is responsible for the cardiovascular liabilities of TZDs (Guan et al., 2005) .
In addition, these mutant mice show dramatically reduced inflammation in fat. They have fewer M1-polarized macrophages (i.e., a subtype of macrophages that produces proinflammatory cytokines), and they display an increased proportion of M2-like macrophages (i.e., a subtype of macrophages with anti-inflammatory properties) (Lumeng et al., 2007) . Fat cells from the mutant mice generate reduced macrophage chemotaxis and are less responsive to macrophage-conditioned media when compared to the fat cells from wild-type animals. Together, these results indicate that activation of PPARg represses both the production of and response to inflammatory signals in fat cells of obese mice.
Deleting NCoR also provides new insights into the mechanism of PPARg regulation. Phosphorylation of PPARg by CDK5 blocks the transcriptional activity of PPARg. Inflammatory cytokines, such as TNFa, can stimulate CDK5, whereas thiazolidinediones and other ligands inhibit phosphorylation by the kinase (Choi et al., 2010) . In a series of binding studies, Li et al. show that NCoR directly modulates the phosphorylation state of PPARg. When bound to the nuclear receptor, NCoR recruits CDK5 into the complex, which facilitates PPARg phosphorylation and repression of its activity. Once NCoR is dissociated due to ligand binding, PPARg remains free from CDK5, unphosphorylated, and transcriptionally active.
In an independent study, Auwerx and colleagues examine the effects of deleting NCoR in skeletal muscle. Although these mutant mice display only modest changes in glucose and lipid homeostasis while on a high-fat diet, they exhibit a substantial increase in oxidative metabolism, mitochondrial content, and muscle fiber size. Compared to the wild-type animals, the mutant mice also display an increase in reprogramming to oxidative muscle and better exercise capacity.
Though the effects of disrupting NCoR in the adipose tissue can be attributed largely to the full activation of PPARg, the transcription factor partners of NCoR in muscle are less certain. (Figure 1 ). NCoR normally keeps the transcriptional activity of its nuclear receptor partners in a basal state. In the case of PPARg in adipocytes, this involves enhancing the binding of CDK5, which ensures that the receptor is phosphorylated and inactive. Thus, NCoR ''keeps a lid'' on lipogenesis and adipogenesis via PPARg. In muscle, NCoR reduces activity of PPARd and ERR, maintaining mitochondrial activity at basal levels and favoring glucose oxidation at the expense of lipid oxidation. When a high-fat diet introduces an excess of calories, it triggers an adaptive downregulation of NCoR in both muscle and adipose tissue, resulting in the increased activity of its partner receptors. This boosts lipogenesis and adipogenesis to provide a storage site for increased fat intake (mimicked by treatment with TZDs), with a coordinated increase in fat oxidation in muscle to maintain energy balance. At the same time, decreased expression of NCoR in fat and possibly in muscle can counteract the effects of obesity-induced inflammation, perhaps as a homeostatic mechanism to maintain inflammation in a low-grade state and promote energy balance within the adipocyte.
Several important questions remain about the role of NCoR in metabolic adaptation. For example, many other transcription factors partner with NCoR. How are these factors influenced by the decreased expression of the corepressor, and how do these factors impact metabolism, particularly in the liver, heart, and brain? Then, what about NCoR's first cousin SMRT, which shares a similar overall structure with NCoR and can form a complex with nuclear receptors? Several reports indicate that steroid hormones, cytokines, and other factors might regulate the expression or cellular localization of NCoR (Perissi et al., 2010 (Choi et al., 2011) to tweak the properties of these multiprotein complexes and drive metabolism in a beneficial direction without unwanted side effects? No doubt these and other questions will spark renewed interest in understanding the pleiotropic actions of corepressors. NCoR is a corepressor of nuclear receptors, including PPARg in adipocytes and PPARd or estrogen-related receptor (ERR) in myocytes. When bound to these transcription factors, NCoR maintains their activity in the basal state. High-fat diet drives down NCoR expression in both tissues, allowing coactivators to bind the nuclear receptors and initiate transcription. In fat cells, this increases lipogenesis and adipogenesis; in muscle, it increases fat oxidation and mitochondrial biogenesis (Li et al., 2011; Yamamoto et al., 2011) .
